Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$36.62 USD
-0.95 (-2.53%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.60 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Vera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 102 | 91 | 34 | 52 | 12 |
Income After Depreciation & Amortization | -102 | -91 | -34 | -52 | -12 |
Non-Operating Income | 10 | 3 | 2 | -1 | 0 |
Interest Expense | 4 | 1 | 0 | 0 | 0 |
Pretax Income | -96 | -89 | -33 | -53 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -96 | -89 | -33 | -53 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -96 | -89 | -33 | -53 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -106 | -92 | -34 | -52 | -11 |
Depreciation & Amortization (Cash Flow) | -4 | -1 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -102 | -91 | -34 | -52 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.71 | 26.57 | 13.44 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.25 | -3.35 | -2.43 | NA | NA |
Diluted Net EPS (GAAP) | -2.25 | -3.35 | -2.43 | -166.93 | NA |
Fiscal Year end for Vera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 31.11 | 27.03 | 21.76 | 21.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -31.11 | -27.03 | -21.76 | -21.97 |
Non-Operating Income | NA | 4.64 | 2.43 | 2.60 | 2.72 |
Interest Expense | NA | 1.91 | 1.06 | 0.94 | 0.91 |
Pretax Income | NA | -28.38 | -25.65 | -20.10 | -20.16 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.38 | -25.65 | -20.10 | -20.16 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.38 | -25.65 | -20.10 | -20.16 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 50.97 | 44.23 | 44.36 | 44.27 |
Diluted EPS Before Non-Recurring Items | NA | -0.56 | -0.58 | -0.45 | -0.46 |
Diluted Net EPS (GAAP) | NA | -0.56 | -0.54 | -0.45 | -0.46 |